
Retatrutide is Eli Lilly’s investigational triple agonist (GLP-1, GIP, glucagon), and the question we hear most often in 2026 is whether it will eclipse tirzepatide for weight loss. Lilly reported on May 21, 2026 that retatrutide produced -28.3% mean weight loss at 12 mg in TRIUMPH-1 (phase 3, n=2,339, 80 weeks, no T2D), versus the -20.2% tirzepatide achieved in SURMOUNT-5. But there is no head-to-head trial, retatrutide cannot be legally compounded, and an active federal court case (Eli Lilly v. Kennedy) has scrambled its FDA classification. This guide answers the question that drives most reader emails: should you wait for retatrutide, or start tirzepatide now?
Table of Contents
- Quick Answer
- At a Glance Comparison
- Mechanism of Action
- Evidence Comparison
- Dosing Protocols
- When to Choose Which
- Community Use Snapshot
- Combinations and Stacking Notes
- Side Effects and Safety
- Drug Interactions
- Cost and Access
- 2026 Regulatory Status
- Frequently Asked Questions
- References
Quick Answer
Retatrutide is not FDA-approved. As of June 1, 2026 the only legitimate way to receive it is to enroll in one of Lilly’s active TRIUMPH trials. Compounded retatrutide is categorically prohibited under federal law; FDA has issued warning letters to more than 50 sellers and compounders, with several naming retatrutide explicitly [6][7]. We do not recommend purchasing compounded retatrutide.
On efficacy, indirect comparison favors retatrutide. TRIUMPH-1 reported -28.3% mean weight loss at 12 mg over 80 weeks (efficacy estimand) [14][15]. SURMOUNT-5 reported -20.2% for tirzepatide at 72 weeks [1]. This is a cross-trial comparison, not a head-to-head: different populations, durations, and estimands. No randomized retatrutide-vs-tirzepatide trial is enrolling. Plausible FDA submission late 2026 to early 2027; possible approval in 2027 (projection).
On regulatory standing, the September 30, 2025 ruling in Eli Lilly v. Kennedy (S.D. Ind., Case 1:24-cv-01503-TWP-KMB, Judge Tanya Walton Pratt) vacated FDA’s classification of retatrutide as a “drug” rather than a “biological product”; the case is on appeal at the D.C. Circuit (25-5226) [11][12][13]. Classification affects 12-year biologic exclusivity versus roughly 5-year drug exclusivity.
If you need treatment now, tirzepatide is the FDA-approved option with the strongest weight-loss evidence outside bariatric surgery. If you can wait into 2027 and meet criteria for severe obesity where the extra efficacy ceiling matters, retatrutide may be worth revisiting after approval. We do not recommend switching off tirzepatide for compounded retatrutide.
At a Glance Comparison
| Feature | Retatrutide | Tirzepatide |
|---|---|---|
| Class | Triple agonist: GLP-1, GIP, glucagon receptors | Dual GIP / GLP-1 receptor co-agonist |
| FDA brands | None; investigational (Lilly code LY3437943) | Mounjaro (T2D, May 2022); Zepbound (weight management, Nov 2023; OSA, Dec 2024) |
| Dosing | TRIUMPH titration: 2 mg start, +4 wk steps (2 / 4 / 8 / 12 mg); phase 3 maintenance 4, 9, 12 mg [4][5] | Titrate 2.5 mg to maintenance 5/10/15 mg subcutaneous weekly |
| Half-life | Approximately 6 days (~144 h); peer-reviewed PK reference not surfaced in this pass [4] | Approximately 5 days (population PK mean 5.4 days) |
| Route | Subcutaneous, once weekly (trial-only) | Subcutaneous, once weekly |
| FDA approval status | Not approved. Plausible submission late 2026 to early 2027; approval potentially 2027 (projection) | Approved 2022 (Mounjaro), 2023 (Zepbound), 2024 (Zepbound OSA) |
| Headline efficacy | -28.3% mean weight loss at 12 mg, 80 weeks (TRIUMPH-1, efficacy estimand, May 2026) [14][15] | -20.2% at max-tolerated 10/15 mg, 72 weeks (SURMOUNT-5, NEJM 2025) [1] |
| Compounding legality | Prohibited. FDA: “Retatrutide and cagrilintide cannot be used in compounding under federal law” [6] | Off shortage list since Dec 2024; April 30, 2026 FDA proposal would exclude tirzepatide from 503B bulks list (comment period through June 29, 2026) [19][20] |
| Cardiovascular indication | TRIUMPH-Outcomes (n~10,000, NCT06383390) enrolling; readout 2027-2028 [22] | SURMOUNT-MMO pending; no CV-outcome label yet |
| 2025-2026 milestones | TRIUMPH-4 readout Dec 2025 (-28.7% at 12 mg, knee OA); TRIUMPH-1 readout May 21, 2026; Lilly v. Kennedy ruling Sept 30, 2025 | Zepbound OSA approval Dec 2024; severe-gastroparesis precaution 2025; April 30, 2026 503B exclusion proposal |
| Likely list price | Not announced; analyst expectation comparable to or above Zepbound (mid-to-high $1,000s/month). Projection. | Zepbound list ~$1,086/month; LillyDirect single-dose vials $299 to $449 |
| Likely black-box warning | MTC and MEN-2 contraindication expected as class effect (if approved) [12] | MTC and MEN-2 contraindication |
Mechanism of Action: Triple vs Dual Agonism
Tirzepatide activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GLP-1 activation drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression. The GIP arm appears to enhance central food-intake regulation and energy expenditure. A C20 fatty diacid supports a 5-day half-life for weekly dosing.
Retatrutide is a single peptide that activates the GLP-1, GIP, and glucagon receptors [1][2]. Its main backbone is 39 alpha amino acids with a second short chain attached via isopeptide bond containing gamma-glutamate and a non-alpha amino acid (ADO) [3]; this structural fact is at the heart of the Lilly v. Kennedy classification dispute (see Regulatory Status).
The glucagon receptor (GCGR) is the mechanistic distinction. In rodent models, glucagon receptor agonism raises resting energy expenditure by roughly 15-20% independent of appetite suppression and accelerates hepatic fat oxidation [2][23]. In caloric-intake-matched obese mice, retatrutide produced greater weight loss than tirzepatide, implying an energy-expenditure contribution on top of appetite suppression [23]. This is the leading hypothesis for retatrutide’s larger efficacy ceiling, though some of the gap is also pure dose-response.
The glucagon arm is also the theoretical risk surface (hyperglycemia, hepatic stress). So far the trial data have been counterintuitively favorable: in the phase 2a MASLD study, ALT decreased on retatrutide and liver fat fell by -82.4% at 12 mg over 24 weeks versus +0.3% on placebo [23]. In phase 2 T2D, retatrutide 12 mg achieved HbA1c reductions of approximately -2.16%, comparable to dulaglutide [1]. One signal does appear genuinely more pronounced with retatrutide than with tirzepatide: cutaneous hyperesthesia and dysesthesia (skin sensitivity, tingling), thought to be glucagon-receptor-mediated. Phase 2 rates: approximately 7% retatrutide vs 1% placebo [1].
Evidence Comparison
No head-to-head trial exists. Anything comparing retatrutide and tirzepatide is indirect cross-trial inference.
TRIUMPH-1: The Headline Phase 3 Readout
| Design element | Detail |
|---|---|
| Citation / status | Lilly investor release, May 21, 2026 [14]. ADA 2026 (June 5-8) detailed data expected; peer-reviewed publication pending as of June 1, 2026 |
| Trial ID | NCT05929066 [13] |
| Sponsor / design | Eli Lilly; phase 3, randomized, double-blind, placebo-controlled |
| Sample size | 2,339 adults randomized |
| Population | Adults with obesity (or overweight) and at least one weight-related comorbidity; T2D excluded |
| Doses | 4 mg, 9 mg, 12 mg vs placebo; 80-week duration |
| Headline (12 mg, efficacy estimand) | -28.3% mean weight loss (about -70.3 lb / -31.9 kg); 45.3% of participants achieved at least 30% weight loss [14][15] |
| Estimand note | Treatment-regimen estimand -24.2%; some outlets cite up to -30.3% from subgroup analyses. We use -28.3% as the headline. |
Honest limitations. Peer-reviewed publication is pending; numbers can shift on full reporting. Lilly designed and sponsored the trial with a placebo (not active) comparator. T2D was excluded, so results do not extrapolate to diabetes (TRIUMPH-2 covers that and has not read out). The 80-week duration is longer than SURMOUNT-1 and SURMOUNT-5 (both 72 weeks), giving retatrutide some headroom in cross-trial comparison.
Cross-Trial Snapshot
| Trial | Drug + dose | Population | Duration | Mean % weight loss |
|---|---|---|---|---|
| SURMOUNT-1 (NEJM 2022) [24] | Tirzepatide 15 mg | Obesity, no T2D | 72 weeks | -22.5% |
| SURMOUNT-5 (NEJM 2025) [1] | Tirzepatide 10/15 mg | Obesity, no T2D | 72 weeks | -20.2% |
| Retatrutide Phase 2 (NEJM 2023) [1] | Retatrutide 12 mg | Obesity, no T2D | 48 weeks | -24.2% |
| TRIUMPH-4 (Dec 2025) [20] | Retatrutide 12 mg | Obesity + knee OA | 68 weeks | -28.7% |
| TRIUMPH-1 (May 2026) [14] | Retatrutide 12 mg | Obesity, no T2D | 80 weeks | -28.3% |
The rest of TRIUMPH. TRIUMPH-2 (T2D + obesity) and TRIUMPH-3 (obesity + established CVD) are expected to read out during 2026. TRIUMPH-4 (n=445, obesity + knee OA, 68 weeks) reported December 2025 with up to -28.7% weight loss at 12 mg, ~75.8% reduction in OA pain endpoints, ~20% LDL reduction, and 72% reversal of prediabetes to normoglycemia [22]. TRIUMPH-Outcomes (n~10,000, MACE and renal composite endpoints) reads out 2027-2028 at the earliest [24].
Honest cross-trial read. Retatrutide appears more potent than tirzepatide for weight loss by an indirect-comparison delta of roughly 5-8 percentage points at peak dose. This is hypothesis-grade evidence, not confirmatory. Until a randomized head-to-head reports, claims that retatrutide “is” superior should carry “in cross-trial comparison” qualifiers.
Dosing Protocols
Retatrutide dosing is for context only. The drug is not available outside trials; we do not support reconstitution of compounded retatrutide.
Retatrutide TRIUMPH titration [4][5]: 2 mg weekly weeks 1-4, then 4 mg weeks 5-8, then 8 mg weeks 9-12 (if tolerated), then 12 mg weekly. TRIUMPH-1 randomized to maintenance arms of 4, 9, and 12 mg. Slow ramp is critical; the 8/12 mg arms produced more GI events than 1/4 mg in phase 2 [1].
Tirzepatide titration (condensed): 2.5 mg weekly for 4 weeks (initiation only), escalating every 4 weeks to 5, then 7.5, then 10 mg; maintenance options 5, 7.5, 10, 12.5, or 15 mg weekly. Detailed protocol in the tirzepatide vs semaglutide guide. Use the tirzepatide calculator to plan reconstitution from FDA-approved Zepbound or Mounjaro pens or vials.
When to Choose Which
| Situation | Tirzepatide (available today) | Retatrutide (investigational) |
|---|---|---|
| You need treatment now | Yes, FDA-approved channels | Not available outside enrolling TRIUMPH trials |
| You can wait into 2027 or later | Reasonable to start now and reassess | Plausible approval window; revisit with your clinician |
| Severe obesity (BMI ≥ 40) where extra efficacy ceiling matters | Strong evidence base; -20% at 15 mg is substantial | Indirect comparison suggests roughly 5-8 pp more weight loss at peak dose; revisit after approval |
| Type 2 diabetes | Tirzepatide: Mounjaro since May 2022, SURPASS-2 superiority over semaglutide 1 mg | TRIUMPH-2 not yet read out; data still maturing |
| MASLD with hepatic steatosis | Tirzepatide MASLD data emerging | Compelling phase 2a signal: -82.4% liver fat at 24 weeks [23]; worth tracking |
| Established cardiovascular disease | SURMOUNT-MMO pending; no CV-outcome label yet | TRIUMPH-Outcomes reads 2027-2028; not actionable today |
| Considering compounded retatrutide | Tirzepatide is the FDA-approved option | No. Federally prohibited, supply chain unverifiable, FDA warning letters on file [6][7][18] |
The framing: if you are considering treatment in 2026, tirzepatide is the FDA-approved option with the strongest weight-loss evidence outside bariatric surgery. If retatrutide becomes available in 2027 or 2028, you and your clinician can revisit. Do not switch from FDA-approved tirzepatide to compounded retatrutide on efficacy hopes.
Community Use Snapshot
The biohacker community has been chasing retatrutide through compounded and “research peptide” sources since phase 2 data published in 2023, with volume rising after TRIUMPH-4 (Dec 2025) and TRIUMPH-1 (May 2026). We are reporting community behavior, not endorsing it. The supply chain for grey-market retatrutide is unverifiable: identity, purity, and concentration are not third-party tested, and FDA has issued more than 50 warning letters since September 2025, several naming retatrutide explicitly [6][7][18]. The PTK editorial position is unambiguous: do not buy compounded retatrutide.
Combinations and Stacking Notes
Some communities discuss adding BPC-157 or TB-500 during a GLP-1 cycle to preserve lean mass; no controlled trials evaluate these combinations with retatrutide or tirzepatide. Better-supported preservation strategies remain adequate protein (1.6 to 2.2 g/kg lean body mass daily) and progressive resistance training. Co-administering investigational retatrutide with any approved GLP-1 (semaglutide, tirzepatide, Foundayo) is not a use case with safety data and is not a path we recommend.
Side Effects and Safety
GI events (nausea, vomiting, diarrhea, constipation) dominate the adverse-event profile for both drugs and concentrate during dose escalation. Cross-program comparison at peak dose suggests retatrutide produces somewhat more GI events than tirzepatide (nausea ~45% vs ~31%) [18], with discontinuation rates trending higher but remaining in the single-digit-percent range comparable to other GLP-1 class agents [1][20]. Slow titration helps.
Liver enzymes. Counterintuitively, ALT decreased on retatrutide in phase 2 obesity and phase 2a MASLD studies (-82.4% relative liver fat reduction at 12 mg, 24 weeks) [1][23]. The net hepatic effect at studied doses is favorable despite the glucagon receptor arm.
Cutaneous hyperesthesia and dysesthesia (skin sensitivity, tingling) appear more often with retatrutide than tirzepatide and are thought to be glucagon-receptor-mediated. Phase 2 rates: ~7% retatrutide vs ~1% placebo [1]. Exact phase 3 rates should be confirmed against the TRIUMPH-1 primary publication when it appears.
Hyperglycemia. The concern that glucagon agonism would worsen glycemic control is not supported by phase 2 T2D data (retatrutide 12 mg achieved -2.16% HbA1c reduction, comparable to dulaglutide) [4]. TRIUMPH-2 will be definitive.
Class warnings. All FDA-approved GLP-1 class agents carry a black-box warning for medullary thyroid carcinoma (MTC), with contraindication in personal or family history of MTC or MEN-2 [8][9]. Retatrutide engages the same GLP-1 receptor and is expected to inherit this warning if approved. Pancreatitis (under 1% in trials), gallbladder disease (more frequent with rapid weight loss), heart-rate increases (~5-10 bpm class effect), and class-wide perioperative aspiration precautions apply to retatrutide as they do to tirzepatide.
Drug Interactions
Delayed gastric emptying can slow absorption of concurrent oral medications, particularly narrow-therapeutic-index drugs and oral contraceptives. Reduce sulfonylurea or insulin doses at GLP-1 initiation to minimize hypoglycemia; increase INR monitoring on warfarin during escalation. The mechanism is shared between retatrutide and tirzepatide, so interaction considerations are broadly similar. See the PTK peptide interactions reference.
Cost and Access
Tirzepatide (FDA-approved channels). Zepbound retail list price is about $1,086 per 28-day pen supply. LillyDirect single-dose vials cost about $299 (2.5 mg), $399 (5 to 10 mg), and $449 (12.5 to 15 mg) self-pay. Commercial insurance with the Lilly savings card can drop copays to as low as $25/month (up to $463/month savings). Medicare Part D covers Mounjaro for T2D; Zepbound coverage is plan-dependent. For current vendor options, see where to buy tirzepatide.
Retatrutide (no legitimate purchase channel). Lilly has not announced a list price. Analyst speculation assumes pricing comparable to or above Zepbound at launch (mid-to-high $1,000s/month plausible). Projection, not fact. Compounded retatrutide is advertised online at $150-$400/month; this is illegal under federal law, the supply chain is unverifiable, and FDA has issued warning letters to multiple sellers [6][7][18]. No “where to buy retatrutide” page exists on this site because no legitimate channel exists. Wait for FDA approval.
2026 Regulatory Status
Three regulatory threads run in parallel in 2026 and are routinely conflated: the Lilly v. Kennedy classification case (specific to retatrutide), the broader GLP-1 compounding crackdown (affects tirzepatide and semaglutide but not retatrutide directly), and the FDA’s research-peptide framework for BPC-157, TB-500, Epitalon, Semax, and others (does not cover any GLP-1 or triple-agonist drug).
Eli Lilly v. Kennedy: The Retatrutide Classification Ruling
Case: Eli Lilly and Company v. Kennedy et al., Case No. 1:24-cv-01503-TWP-KMB (S.D. Ind.), filed September 3, 2024 [11][12]. Decision September 30, 2025: Judge Tanya Walton Pratt vacated FDA’s classification of retatrutide as a “drug” rather than a “biological product,” holding that FDA’s “bright-line” 40-amino-acid threshold “flouts the statutory text and sidesteps congressional intent” [11][14]. The structural fact at issue: retatrutide’s main backbone is 39 alpha amino acids (one short of FDA’s bright line), with a second short chain attached via isopeptide bond containing gamma-glutamate and a non-alpha amino acid (ADO) [3].
Stakes: a biologic gets 12 years of reference-product exclusivity; a small-molecule drug gets roughly 5 years. Biologic status also changes the compounding framework [12][15]. The appeal is pending at D.C. Circuit Case 25-5226 [17]. As of June 2026, FDA has not redetermined retatrutide’s classification on remand; retatrutide remains investigational regardless of how the classification resolves. This is the single most significant regulatory development specific to retatrutide.
Compounded Retatrutide Is Categorically Prohibited
FDA’s position is explicit: “Retatrutide and cagrilintide cannot be used in compounding under federal law” [6]. Retatrutide fails all three 503A and 503B eligibility criteria: no USP/NF monograph, not a component of any FDA-approved drug, and not on the 503A bulks list nor the 503B interim bulks list [6][7]. FDA issued warning letters in September 2025 to more than 50 compounders and online sellers, with several letters specifically naming retatrutide [6][7][18]. “Research peptide” labeling that includes human dosing instructions does not change the legal analysis.
The Broader GLP-1 Compounding Framework (Separate Track)
On April 15, 2026, FDA removed 12 previously-restricted peptides from Category 2 of the 503A interim bulks list; retatrutide was not on that list, and this action does not change its status. On April 30, 2026, FDA published a proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list; comment period closes June 29, 2026 [19][20]. The July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting covers seven research peptides (BPC-157, TB-500, Epitalon, Semax, Emideltide, and two others) and is not about retatrutide, tirzepatide, or semaglutide. Coverage that conflates these tracks is incorrect on the law.
Expected Approval Pathway
TRIUMPH-2 and TRIUMPH-3 are expected to read out during 2026. Plausible FDA submission is late 2026 to early 2027; possible approval mid-to-late 2027 on standard review. TRIUMPH-Outcomes reads out 2027-2028, likely required for a CV indication. The submission pathway depends on the Lilly v. Kennedy appeal: BLA (biologic) if upheld, NDA (drug) if reversed. All projections. Lilly has not publicly committed to a submission date.
Frequently Asked Questions
Is retatrutide better than tirzepatide?
In indirect comparison, retatrutide produced more weight loss: -28.3% at 12 mg in TRIUMPH-1 (80 weeks, May 2026) vs -20.2% for tirzepatide in SURMOUNT-5 (72 weeks); plausible delta roughly 5-8 percentage points at peak dose. Hypothesis-grade evidence, not a confirmed head-to-head result. No randomized retatrutide-vs-tirzepatide trial has reported or is currently enrolling. Tirzepatide has the longer real-world record, FDA approval, and established T2D indication; retatrutide has the higher efficacy ceiling in trials reported so far.
Can I buy retatrutide now?
Not legitimately. As of June 1, 2026 retatrutide is investigational. The only legal way to receive it is to enroll in an active TRIUMPH trial. Compounded and “research peptide” retatrutide are sold online but are prohibited under federal law (see next question); the supply chain is unverifiable and FDA has issued warning letters to multiple sellers [6][7][18].
Is compounded retatrutide legal?
No. FDA’s statement is explicit: “Retatrutide and cagrilintide cannot be used in compounding under federal law” [6]. Retatrutide fails all three 503A/503B eligibility criteria (no USP/NF monograph, not a component of any FDA-approved drug, not on the 503A bulks list). FDA issued warning letters in September 2025 to more than 50 sellers and compounders, with several naming retatrutide explicitly [7][18].
When will retatrutide be FDA-approved?
Plausibly 2027 on a standard review. Lilly has not committed to a submission date. The full TRIUMPH program is reading out across 2026 and into 2027-2028. The approval pathway also depends on the Lilly v. Kennedy appeal (D.C. Circuit Case 25-5226): a biologic application would carry 12 years of reference-product exclusivity, a drug application roughly 5 years. Treat all timelines as projections.
What about side effects compared to tirzepatide?
The GI profile is qualitatively similar to tirzepatide but somewhat more frequent at peak dose in cross-program comparison. Liver enzymes have moved in the favorable direction despite the glucagon arm, which was the main theoretical concern. Cutaneous hyperesthesia and dysesthesia (skin sensitivity, tingling) appear more often with retatrutide and are thought to be glucagon-receptor-mediated. MTC and MEN-2 class warnings will likely apply to retatrutide as they do to tirzepatide.
Should I switch from tirzepatide to retatrutide when it’s approved?
That is a clinical decision to make with your prescriber after approval, with the actual label and pricing in hand. Factors favoring a switch: severe obesity where the extra 5-8 percentage points meaningfully affects clinical outcomes, MASLD with significant hepatic steatosis. Factors favoring staying on tirzepatide: a working response, established insurance coverage, T2D where Mounjaro has the longer track record. We do not recommend switching off tirzepatide for compounded retatrutide under any circumstances.
Bottom Line: The Honest Comparison
Tirzepatide wins for availability today, FDA-approved indications across T2D, chronic weight management, and moderate-to-severe OSA, a long real-world record, and established insurance pathways. Retatrutide wins (in indirect comparison) for peak weight loss (-28.3% at 12 mg vs -20.2% for tirzepatide) and the largest liver-fat reduction reported with any pharmacotherapy in this class, on a mechanism that adds glucagon receptor agonism to GIP+GLP-1.
Honest caveat: TRIUMPH-1 is a Lilly-sponsored placebo-controlled phase 3 with peer-reviewed publication still pending. The cross-trial comparison to SURMOUNT-5 is not a head-to-head. Retatrutide is not for sale anywhere outside a clinical trial today, the Lilly v. Kennedy ruling is on appeal, and the TRIUMPH program is still mid-readout. If you are weighing the decision today, tirzepatide is the answer. Revisit retatrutide after FDA approval.
Open the PTK calculator and start planning your tirzepatide protocol
Read Next
- Tirzepatide vs semaglutide: full comparison
- Where to buy tirzepatide: current vendors and pricing
- Peptide and drug interactions checker
- Our editorial methodology
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med 2023. DOI 10.1056/NEJMoa2301972. nejm.org.
- Triple Agonism-Based Therapies for Obesity. Current Cardiovascular Risk Reports. Springer Nature. 2025. link.springer.com.
- Goodwin LLP / Big Molecule Watch. Eli Lilly Files Suit Challenging the FDA’s Drug Classification of Retatrutide. September 24, 2024. bigmoleculewatch.com.
- Retatrutide Dosing Guide 2026: 2 mg to 12 mg Protocol, Half-Life. PeptideDeck. peptidedeck.com. (Secondary source; primary peer-reviewed PK reference not surfaced.)
- Retatrutide Dosing / TRIUMPH Titration. Remy Peptides. remypeptides.com. (Secondary.)
- FDA position on compounded retatrutide and cagrilintide; Arizona Osteopathic Board republication of FDA letter regarding retatrutide. azdo.gov.
- FDA. Warning Letter to GLP-1 Solution (715883). September 9, 2025. fda.gov.
- FDA. Mounjaro (tirzepatide) Injection Prescribing Information. May 2022. accessdata.fda.gov.
- FDA. Zepbound (tirzepatide) Prescribing Information. November 2023, most recent revision 2025. pi.lilly.com.
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025;392:2127-2139. DOI 10.1056/NEJMoa2416394. nejm.org.
- U.S. District Court, S.D. Indiana. Eli Lilly and Company v. Kennedy et al., Case No. 1:24-cv-01503-TWP-KMB. Decision filed September 30, 2025. govinfo.gov.
- Big Molecule Watch (Goodwin LLP). Eli Lilly Files Suit Challenging the FDA’s Drug Classification of Retatrutide. bigmoleculewatch.com.
- Bloomberg Law. Lilly Gets Partial Win in Suit Over FDA’s Biologic Determination. October 2025. bloomberglaw.com.
- Goodwin LLP. District Court Sets Aside FDA’s Interpretation of “Analogous” to a Protein. October 2025. goodwinlaw.com.
- Inside Indiana Business. Lilly seeks court ruling that could mean big money for new weight-loss drug. insideindianabusiness.com.
- TrialSiteNews. Eli Lilly v. Kennedy: When Is a Peptide a Protein? trialsitenews.com.
- Endpoints News. Lilly appeals ruling over retatrutide classification (D.C. Circuit Case 25-5226). endpoints.news.
- Lengea Law. FDA Warns Companies Over Compounded Retatrutide. lengealaw.com.
- FDA. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Federal Register, April 30, 2026. fda.gov.
- Pharmacy Times. FDA Moves to Permanently Close the Door on Compounded GLP-1s. pharmacytimes.com.
- Eli Lilly investor release. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). May 21, 2026. investor.lilly.com.
- Eli Lilly investor release. Retatrutide TRIUMPH-4 readout (obesity + knee OA). December 2025. investor.lilly.com.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024. nature.com.
- ClinicalTrials.gov. NCT05929066 (TRIUMPH-1) / NCT05929079 (TRIUMPH-2) / NCT05882045 (TRIUMPH-3) / NCT05931367 (TRIUMPH-4) / NCT06383390 (TRIUMPH-Outcomes). clinicaltrials.gov.
